Minocycline
Ischemic Stroke
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Beijing Tiantan Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07594314CT.gov Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA) | — | Recruiting | — | — | — |
NCT07594301CT.gov Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP) | — | Recruiting | — | — | — |
NCT07526987CT.gov Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis | — | Not Yet Recruiting | — | — | — |
NCT07237048CT.gov Minocycline in Stroke Study at Maimonides | — | Recruiting | — | — | — |
NCT05367362CT.gov Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke | — | Withdrawn | — | — | — |
NCT06107725CT.gov Maimonides Minocycline in Stroke Study | — | Terminated | — | — | — |
NCT05836740CT.gov Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke | — | Completed | — | — | — |
NCT05512910CT.gov Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B) | — | Active Not Recruiting | — | — | — |
NCT05487417CT.gov Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy | — | Recruiting | — | — | — |
NCT05032781CT.gov Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention | — | Withdrawn | — | — | — |
Show 2 more trialsShow fewer
NCT03320018CT.gov Neuroprotection in Acute Ischemic Stroke | — | Completed | — | — | — |
NCT00836355CT.gov Enoxaparin and/or Minocycline in Acute Stroke | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ischemic Stroke
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Minocycline (this asset) | Beijing Tiantan Hospital | Approved | BB · 64 |
| Ticagrelor | Sichuan Provincial People's Hospital | P4 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Compound Edaravone | Nanfang Hospital, Southern Medical University | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Nanfang Hospital, Southern Medical University | P4 | BBB |
| Argatroban | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Tenecteplase | Hackensack Meridian Health | P4 | BBB |
| Aspirin | Nanfang Hospital, Southern Medical University | P4 | BB |
| Prednisolone | University of California, San Francisco | P4 | BB |
+42 more in the Ischemic Stroke cohort
Other indications for Minocycline
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mood Disorder | — | P4 | BBB · 73 |
| Bipolar Depression | — | P4 | BB · 70 |
| Schizophrenia | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Minocycline in Ischemic Stroke. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/minocycline-ischemic-stroke-125753
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →